Affordable Access

Access to the full text

Hepatitis B virus (HBV) infection amongst children in Senegal: current prevalence and seroprotection level

  • Lô, Gora1, 2
  • Sow-Sall, Amina1
  • Diop-Ndiaye, Halimatou1, 3
  • Babacar, Ndiaye3
  • Diouf, Niokhar Ndane4
  • Daffé, Sokhna Moumi2
  • Ndao, Babacar2
  • Thiam, Moussa1
  • Mbow, Moustapha1
  • Soumboundou, Mamadou Bayo5
  • Lemoine, Maud6
  • Sylla-Niang, Maguette4
  • Ndiaye, Ousseynou7
  • Boye, Cheikh Saad3
  • Mboup, Souleymane1
  • Touré-Kane, Ndeye Coumba1, 8
  • 1 Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Sénégal
  • 2 Centre Médical Inter Armées Lemonier, Dakar, Senegal
  • 3 Laboratoire de Bactériologie, Virologie de l’Hôpital Aristide Le Dantec, Dakar, Sénégal
  • 4 Hôpital Général de Grand, Yoff, Senegal
  • 5 Hôpital pour Enfant de Diamniadio, Dakar,Sénégal
  • 6 Imperial College London, St Mary’s Hospital campus, London, UK
  • 7 Hôpital Albert Royer de Dakar, Sénégal
  • 8 Hôpital Dalal Diamm, Dakar, Sénégal
Published Article
Pan African Medical Journal
Pan African Medical Journal
Publication Date
Mar 25, 2019
DOI: 10.11604/pamj.2019.32.140.14485
PMID: 31303913
PMCID: PMC6607249
PubMed Central


Introduction Hepatitis B virus (HBV) infection is highly endemic in Senegal. HBV vaccine of all children has been introduced in 1999 and included in the Expanded Programme on Immunization in 2004. The aim of this study was to assess the HBV prevalence and immunity status against HBV amongst children in Senegal. Methods Between March and August 2016, consecutive children aged from 6 months to 16 years old were recruited in outpatient department of three main children hospitals in Senegal. Serum samples were analyzed for HBV serology (HBsAg, HBcAb, HBsAb) using ARCHITECT analyzer. Children with HBsAb levels ≥ 10 IU/l) were considered as seroprotected against HBV. Results During the study period, 295 children fulfilled the criteria for the study and were further analyzed. Three children were HBsAg positive giving a seroprevalence at 1.1% (95% CI: 0.2-3.3), 12/267 (4.5%, 95% CI=2.3-7.7) had positive HBcAb and 226/295 (76.6%, 71.4-81.3) had positive HBsAb including 191 (77.3%, 71.6-82.4) with isolated HBsAb related to previous active immunization. However only 165 children (56%, CI 50-62) had seroprotective HBsAb levels (HBsAb ≥ 10 UI/L) and 63 (21.4, 16.8-26) had a strong seroprotectiondefined by HBsAb ≥ 100 IU/L. Conclusion Our results suggest that although HBV prevalence has significantly decreased in children in Senegal following a better HBV vaccine coverage, the number of children correctly seroprotected is insufficient (56%). Assessing the levels of HBsAb and providing HBV vaccine boosters should be considered in children in Senegal.

Report this publication


Seen <100 times